Thyroid Gland Medullary Carcinoma — Trials

Thyroid Gland Medullary Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

105 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 25
Recruiting: 8
Ph III recruiting: 1
Growth YoY: —
Industry share: 32%
Top sponsor: Eli Lilly and Company
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (11)

clinicaltrialsPublishedShowing 1–3 of 3 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03906331	Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation	approved for marketing	—	—	Eli Lilly and CompanyINDUSTRY	13	Jan 17, 2025	clinicaltrials
NCT04204928	Pre-Approval Access Program (PAAP) for Pralsetinib (BLU-667) in Patients With Unresectable or Metastatic NSCLC or MTC	approved for marketing	—	—	Blueprint Medicines CorporationINDUSTRY	0	Aug 13, 2021